We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative vaccines for a healthier world


Advancing groundbreaking vaccines through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.
Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.
Latest news
ExpreS2ion announces financial results for the fourth quarter of 2024
Hørsholm, Denmark, 6 February 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion to Present in Upcoming Investor and Scientific Events
Hørsholm, Denmark, 9 January 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk – the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark.
Read morePublication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet Infectious Diseases titled “Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children”. The article is based on a…
Read more